SIRPA and neoplasm: In view of the interaction between CD47 and SIRPα in tumor cells restricts the anti-tumor immune response, treatment with anti-CD47 antibodies that restrain CD47 signaling in tumor cells was able to induce the phagocytosis of tumor cells by macrophages and stimulate anti-tumor immune responses in vivo (45).